

APPENDIX: Claims as currently pending.

4. (amended) A method for inhibiting skin disorders selected from the group consisting of lymphangiogenesis, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, recessive dystrophic epidermolysis bullosa, venous ulcers, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis.

5. The method of claim 4 wherein the angiogenesis inhibitor is applied topically.

6. The method of claim 5 wherein the angiogenesis inhibitor is selected from the group consisting of collagenase inhibitors, endostatin, angiostatin, fumagillin derivatives like TNP-470, 2,5-diaryltetrahydrofurans, aminophenylphosphonic acid compounds, 3-substituted oxindole derivatives, thalidomides, penicillamine and IL12.

10. A method to treat a disorder selected from the group consisting of angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Kaposi's sarcoma, and psoriasis, comprising administering to the individual in need of treatment an effective amount to inhibit angiogenesis of a curcuminoid.

11. The method of claim 10 wherein the angiogenesis inhibitor is curcumin.

12. The method of claim 10 wherein the angiogenesis inhibitor is demethoxycurcumin.

13. (amended) A pharmaceutical composition comprising a curcumin in combination with a pharmaceutically acceptable carrier for topical administration, wherein the curcumin is present in a dosage effective to treat a condition selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis, wherein the carrier is an ointment containing between one-half percent (0.5%) and five percent (5%) of the curcuminoid or a polymer formulation for implantation.

14. (amended) The composition of claim 13 wherein the carrier is an ointment.

15. (amended) The composition of claim 14 as an ointment [or hydrogel] containing between one-half percent (0.5%) and five percent (5%) of the curcuminoid.

16. The composition of claim 13 wherein the carrier is a polymer formulation for implantation.

17. A method for inhibiting skin disorders selected from the group consisting of lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis comprising administering to the individual in need of treatment thereof an angiogenesis inhibitor in an amount effective to inhibit angiogenesis, wherein the angiogenesis inhibitor is selected from the group consisting of

U.S.S.N. 09/765,491
Filed: January 18, 2001
RESPONSE TO RESTRICTION REQUIREMENT

tetracyclines inhibiting collagenase,
endostatin,
a sulfated polysaccharide which inhibits angiogenesis.

ATL1 #480191 v1